Skip to content

JBIO JBIO Change in Accrued Liabilities

Change in Accrued Liabilities at other companies

Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
-$20.9M-119%
Vera Therapeutics logo
Vera TherapeuticsVERA
-$437K+90.9%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-$1.5M+12.1%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-$23.69M-48.9%
Annexon logo
AnnexonANNX
-$9.4M-421%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$2.33M+91.4%

Other financials

Income statement

See full
Operating income-$43.4M-85.8%
Net income-$40.4M-5.8%
EPS (diluted)-$0.57+95.3%

Balance sheet

See full
Cash & equivalents$55.1M+24.6%
Total debt$808.0K+159%
Total equity$296.5M+455%
Total assets$319.4M+312%

Cash flow

See full
Operating cash flow-$24.1M-28.4%
CapEx$3.0K
Free cash flow-$33.7M

Valuation

See full
Market cap$1.33B+318%
Enterprise value$1.28B

Returns & leverage

See full
Return on equity-132.5%+120pp
Debt / equity
Current ratio14.3×-17.7×

Where this comes from

Reported directly by JBIO in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.

The official record: JBIO’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about JBIO's change in accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is JBIO's change in accrued liabilities?
JBIO (JBIO) reported change in accrued liabilities of $5.77M in Q1 2026.
How has JBIO's change in accrued liabilities changed year-over-year?
JBIO's change in accrued liabilities increased by 396.3% year-over-year, from -$1.95M to $5.77M.
What is the long-term trend for JBIO's change in accrued liabilities?
Over 2 years (2022 to 2024), JBIO's change in accrued liabilities has grown at a -33.6% compound annual growth rate (CAGR), from $3.98M to $1.75M.
What does change in accrued liabilities mean?
Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.